Deal Announcement Syrinx Bioanalytics Oy

Type of deal: Sale of shares

Sector: Healthcare

Object of sale: PwC Finland acted as legal advisor to the shareholders of Syrinx Bioanalytics Oy in the sale of 100% shares in the company to Synexa Life Sciences Finland Oy, which is part of Synexa Life Sciences Group.

Syrinx Bioanalytics Oy is a bioanalytical service provider and CRO based in Turku, Finland, specialising in high-quality bioanalysis for biopharma drug development programs. Syrinx develops and validates methods and analyses biological samples for the determination of biomarkers and anti-drug antibodies in compliance with health authority requirements.

Sellers: Private persons

Buyer: Synexa Life Sciences Finland Oy

Deal announcement date: 19 May 2022

PwC's role: Sellers’ legal advisor

Press release